Management of seasonal allergic conjunctivitis: Guide to therapy

Acta Ophthalmologica

Volumn 90, Issue 5, 2012, Pages 399-407

  Bielory, Brett P ^a   O'Brien, Terrence P ^a   Bielory, Leonard ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Rutgers University Center for Climate Prediction   (United States)

Author keywords

allergic rhinitis; C 20 ester corticosteroid; C 20 ketone corticosteroid; loteprednol etabonate; seasonal allergic conjunctivitis

Indexed keywords

ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; CARBON; CORTICOSTEROID; DECONGESTIVE AGENT; HISTAMINE H1 RECEPTOR; INTERLEUKIN 4; LOTEPREDNOL ETABONATE; LUBRICATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE ACETATE; STABILIZING AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ALLERGIC RHINITIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; BURNING SENSATION; CATARACT; CATARACTOGENESIS; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CLOSED ANGLE GLAUCOMA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC PREDISPOSITION; GLAUCOMA; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MACROPHAGE; MAST CELL; MORBIDITY; MYDRIASIS; NEUTROPHIL; PARALYSIS; PATHOPHYSIOLOGY; PHOTOPHOBIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; SEASONAL ALLERGIC CONJUNCTIVITIS; SYMPTOMATOLOGY; T LYMPHOCYTE; TASTE DISORDER; WOUND HEALING IMPAIRMENT;

ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 84864413473     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02272.x     Document Type: Review

References (71)

1. Abelson MB, (1998): Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 81: 211-218. (Pubitemid 28464704)
2. Abelson M, Howes J, &, George M, (1998): The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 14: 533-542. (Pubitemid 28566794)
3. Alexander M, Berger W, Buchholz P, Walt J, Burk C, Lee J, Arbuckle R, &, Abetz L, (2005): The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 3: 67.
4. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, &, Blanco-Quirõs A, (1994): Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 93: 556-566. (Pubitemid 24105060)
5. American Academy of Allergy, Asthma & Immunology (2000): The allergy report. Volume 3: conditions that may have an allergic component. Milwaukee, WI: American Academy of Allergy, Asthma & Immunology, 1-158.
6. American Academy of Ophthalmology (2003): Conjunctivitis, preferred practice pattern. Available at:. Accessed September 19, 2008. San Francisco: CA, 1-41.
7. Armaly MF, (1965): Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 4: 187-197.
8. Asbell P, &, Howes J, (1997): A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 23: 31-36. (Pubitemid 27043763)
9. Barney NP, &, Graziano FM, (2003): Allergic and immunologic diseases of the eye. In:, Adkinson NFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, &, Simons FE, (eds). Middleton's allergy: principles & practice, vol. 2. St. Louis, MO: Mosby, 1599-1617.
10. Bartlett JD, Horwitz B, Laibovitz R, &, Howes JF, (1993a): Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 9: 157-165. (Pubitemid 23187584)
11. Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R, &, Horwitz B, (1993b): Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 12: 313-321. (Pubitemid 23162150)
12. Belvisi MG, &, Hele DJ, (2003): Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 16: 321-325. (Pubitemid 37315855)
13. Bhargava A, Jackson WB, &, El-Defrawy SR, (1998): Ocular allergic disease. Drugs Today (Barc) 34: 957-971. (Pubitemid 29079257)
14. Bielory L, (2000): Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J Allergy Clin Immunol 106: 805-816.
15. Bielory L, (2002a): Ocular allergy guidelines: a practical treatment algorithm. Drugs 62: 1611-1634. (Pubitemid 34848369)
16. Bielory L, (2002b): Update on ocular allergy treatment. Expert Opin Pharmacother 3: 541-553. (Pubitemid 34520864)
17. Bielory L, (2006): Allergic diseases of the eye. Med Clin North Am 90: 129-148. (Pubitemid 41682034)
18. Bielory L, (2007): Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 98: 105-114.
19. Bielory L, (2008): Ocular allergy treatment. Immunol Allergy Clin North Am 28: 189-224. (Pubitemid 351241103)
20. Bielory L, &, Friedlaender M, (2008): Allergic conjunctivitis. Immunol Allergy Clin North Am 28: 43-58. (Pubitemid 351241107)
21. Bielory L, &, Ghafoor S, (2005): Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 5: 437-440. (Pubitemid 41345313)
22. Bielory L, &, Mongia A, (2002): Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2: 447-452. (Pubitemid 35239528)
23. Bielory L, Goodman PE, &, Fisher EM, (2001): Allergic ocular disease. A review of pathophysiology and clinical presentations. Clin Rev Allergy Immunol 20: 183-200. (Pubitemid 32374977)
24. Bielory L, Buddiga P, &, Bigelson S, (2004): Ocular allergy treatment comparisons: azelastine and olopatadine. Curr Allergy Asthma Rep 4: 320-325. (Pubitemid 39359534)
25. Bielory L, Katelaris CH, Lightman S, &, Naclerio RM, (2007): Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 9: 35.
26. Bodor N, &, Buchwald P, (2005): Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 7: E820-E833.
27. Bousquet J, Khaltaev N, Cruz AA, et al., (2008): Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63 (Suppl 86): 8-160. (Pubitemid 351357811)
28. Broide DH, (2007): The pathophysiology of allergic rhinoconjunctivitis. Allergy Asthma Proc 28: 398-403.
29. Butrus S, &, Portela R, (2005): Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 18: 485-492. (Pubitemid 41728018)
30. Carnahan MC, &, Goldstein DA, (2000): Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11: 478-483.
31. Chambless SL, &, Trocme S, (2004): Developments in ocular allergy. Curr Opin Allergy Clin Immunol 4: 431-434. (Pubitemid 39274086)
32. Chang J, McCluskey P, &, Wakefield D, (2006): Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 90: 103-108. (Pubitemid 43029907)
33. Dell SJ, Shulman DG, Lowry GM, &, Howes J, (1997): A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 123: 791-797. (Pubitemid 27250926)
34. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, &, Hart K, (1998): A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 102: 251-255.
35. Donovan J, Buckeridge D, Briscoe M, Clark R, &, Day J, (1996): Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 77: 74-80. (Pubitemid 26324156)
36. Friedlaender MH, &, Howes J, (1997): A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 123: 455-464. (Pubitemid 27171850)
37. Holland EJ, Bartlett JD, Paterno MR, Usner DW, &, Comstock TL, (2008): Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 27: 50-55.
38. Holland E, Djalilian A, &, Sanderson J, (2009): Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 28: 1139-1143.
39. Ilyas H, Slonim CB, Braswell GR, Favetta JR, &, Schulman M, (2004): Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30: 10-13. (Pubitemid 43196972)
40. Ito Y, Takahashi Y, Fujita T, &, Fukuyama S, (1997): Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Auris Nasus Larynx 24: 163-170. (Pubitemid 27171531)
41. Jones R 3rd, &, Rhee DJ, (2006): Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 17: 163-167. (Pubitemid 43790812)
42. Leibowitz HM, Bartlett JD, Rich R, McQuirter H, Stewart R, &, Assil K, (1996): Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 114: 933-937. (Pubitemid 26271457)
43. Leonardi A, (2002): The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2: 325-331.
44. Leonardi A, Curnow SJ, Zhan H, &, Calder VL, (2006): Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 36: 777-784. (Pubitemid 43972973)
45. Leonardi A, De Dominicis C, &, Motterle L, (2007): Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 7: 429-435. (Pubitemid 47415288)
46. Loteprednol Etabonate Postoperative Inflammation Study Group 2 (1998): A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 105: 1780-1786.
47. Loteprednol Etabonate US Uveitis Study Group (1999): Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 127: 537-544.
48. Manabe S, Bucala R, &, Cerami A, (1984): Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 74: 1803-1810. (Pubitemid 15214094)
49. McGhee CN, Dean S, &, Danesh-Meyer H, (2002): Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25: 33-55. (Pubitemid 34208330)
50. Meyer D, (2006): Current concepts in the therapeutic approach to allergic conjunctivitis. Curr Allergy Clin Immunol 19: 65-68.
51. Mindel JS, Tavitian HO, Smith H Jr, &, Walker EC, (1980): Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol 98: 1577-1578. (Pubitemid 10001101)
52. Novack GD, (2002): Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model. Clin Ther 24: 1477-1478; author reply 1478-1480.
53. Novack GD, Howes J, Crockett RS, &, Sherwood MB, (1998): Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 7: 266-269. (Pubitemid 29149820)
54. Ono SJ, &, Abelson MB, (2005): Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115: 118-122. (Pubitemid 40075430)
55. Pearlman DS, (1999): Pathophysiology of the inflammatory response. J Allergy Clin Immunol 104: S132-S137. (Pubitemid 30249318)
56. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, &, Bron AJ, (2004): Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11: 17-33. (Pubitemid 38367076)
57. Schacke H, Docke WD, &, Asadullah K, (2002): Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43. (Pubitemid 35346616)
58. Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, &, Hart K, (1999): A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 106: 362-369. (Pubitemid 30191638)
59. Singh K, &, Bielory L, (2007a): Epidemiology of ocular allergy symptoms in United States adults (1988-1994). Abstract 35. Ann Allergy Asthma Immunol 98: A22.
60. Singh K, &, Bielory L, (2007b): Ocular allergy: a national epidemiologic study. Abstract 604. J Allergy Clin Immunol 119: S154.
61. Smith AF, Pitt AD, Rodruiguez AE, et al., (2005): The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 12: 233-242. (Pubitemid 41702805)
62. Spector S, &, Raizman M, (1994): Conjunctivitis medicamentosa. J Allergy Clin Immunol 94: 134-136. (Pubitemid 24219669)
63. Stahl JL, &, Barney NP, (2004): Ocular allergic disease. Curr Opin Allergy Clin Immunol 4: 455-459. (Pubitemid 39274090)
64. Stahn C, Lowenberg M, Hommes DW, &, Buttgereit F, (2007): Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275: 71-78. (Pubitemid 47259281)
65. The Medical Letter (2007): Drugs for some common eye disorders. Treat Guidel Med Lett 5: 1-8.
66. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, &, Chalam KV, (1999): Corticosteroids and glaucoma risk. Drugs Aging 15: 439-450. (Pubitemid 30025747)
67. Urban RC Jr, &, Dreyer EB, (1993): Corticosteroid-induced glaucoma. Int Ophthalmol Clin 33: 135-139. (Pubitemid 23155404)
68. Wallace DV, Dykewicz MS, Bernstein DI, et al., (2008): The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 122: S1-S84. (Pubitemid 352033573)
69. White EM, Macy JI, Bateman KM, &, Comstock TL, (2008): Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 24: 287-296. (Pubitemid 351181204)
70. Woodward DF, Nieves AL, Williams LS, Gary RK Jr, Wasserman MA, &, Gleason JG, (1989): Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity. Eur J Pharmacol 164: 323-333. (Pubitemid 19138639)
71. Woodward DF, Nieves AL, Hawley SB, Joseph R, Merlino GF, &, Spada CS, (1995): The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 11: 339-347.